Dexrazoxane for Injection
Brand Names: Dexrazoxane for Injection Generic
Methodology & AI Transparency ⓘ
Dexrazoxane for Injection Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Dexrazoxane for Injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control.
- 2 Real-world patient consensus: Zero-PHI community consensus: 81% favorable across 15 logged regimens (Dexrazoxane for Injection Generic).
- 3 Typical cash cost range: Public pharmacy ledger: $42.12 low cash benchmark vs. $103.19 chain retail average ($0.8300/unit CMS NADAC).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Dexrazoxane for Injection): nausea (8.5%), headache (7.1%), dizziness (5.1%).
Ask our AI Specialists anything about Dexrazoxane for Injection
Dexrazoxane for Injection Mechanism, CYP450 Pathways & DailyMed Monograph
Dexrazoxane for Injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy .
12.1 Mechanism of Action The mechanism by which Dexrazoxane for Injection exerts its cytoprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of EDTA that penetrates cell membranes. Results of laboratory studies suggest that dexrazoxane is converted intracellularly to a ring-opened chelating agent that interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy.
With Mean elimination half-life of 7 to 17 hours across adult Dexrazoxane for Injection dosing residence kinetics and Complete (~100%) parenteral systemic delivery for Dexrazoxane for Injection (500 mg/50mL Injection, Powder, Lyophilized, for Solution) bioavailability, Dexrazoxane for Injection undergoes dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of dexrazoxane for injection and establishes therapeutic activity over rapid intravascular/parenteral onset within 15–45 minutes after dexrazoxane for injection administration.
Standard adult regimens span 500 mg/50mL Injection, Powder, Lyophilized, for Solution, 250 mg/25mL Injection, Powder, Lyophilized, for Solution. Prescribers screen specifically against do not use dexrazoxane for injection with non-anthracycline chemotherapy regimens.; dexrazoxane for injection should not be used with non-anthracycline chemotherapy regimens., while community micro-logs most frequently note nausea (8.5% of reports), headache (7.1% of reports), fatigue (5.4% of reports).
Separate Dexrazoxane for Injection ingestion from mineral supplements or antacids to preserve gastrointestinal bioavailability.
Reconcile eGFR-adjusted medications before escalating Dexrazoxane for Injection in polypharmacy regimens.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Do not use Dexrazoxane for Injection with non-anthracycline chemotherapy regimens.
- Dexrazoxane for Injection should not be used with non-anthracycline chemotherapy regimens.
Logged Side-Effect Incidence (15 Reports)
Dexrazoxane for Injection Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Dexrazoxane for Injection)
Human clinical trial evidence for Dexrazoxane for Injection is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Dexrazoxane for Injection Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.8300/unit (~$24.90/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $103.19 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 15 Anonymous DotMD Community Micro-Logs | $42.12 / mo | View logs ↓ |
Dexrazoxane for Injection Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Dexrazoxane for Injection RxNorm Concept ID | 1736590 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.8300 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $103.19 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $42.12 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 81.00% Worth It (15 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Dexrazoxane for Injection Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Dexrazoxane for Injection: FDA labeling (2025-08-01, NDC 72611-716), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Dexrazoxane for Injection community threads and patient logs by age, biological sex, dosage, and treatment duration.